section name header

Pronunciation

sye-ME-ti-deen

Classifications

Therapeutic Classification: antiulcer agents

Pharmacologic Classification: histamine h2 antagonists

Indications

REMS


Unlabeled Use:
  • Management of GI symptoms associated with the use of NSAIDs.
  • Management of urticaria.

Action

  • Inhibits the action of histamine at the H2-receptor site located primarily in gastric parietal cells, resulting in inhibition of gastric acid secretion.
Therapeutic effects:
  • Healing and prevention of ulcers.
  • Decreased symptoms of gastroesophageal reflux.
  • Decreased secretion of gastric acid.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Enters breast milk and cerebrospinal fluid.

Metabolism/Excretion: 30% metabolized by the liver; remainder is eliminated unchanged by the kidneys.

Half-Life: 2 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
PO30 min45–90 min4–5 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ARRHYTHMIAS

Endo: gynecomastia

GI: constipation, diarrhea, hepatitis, nausea

GU: sperm count, erectile dysfunction

Hemat: anemia, AGRANULOCYTOSIS, APLASTIC ANEMIA, neutropenia, thrombocytopenia

Neuro: confusion, dizziness, drowsiness, hallucinations, headache

Misc: hypersensitivity reactions

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Tagamet